Table 4 Results of CUA of CKD patients undergoing kidney transplant included in the review

CUA of transplanting infectious kidneys (n = 03)

 Kadatz et al. [26]

Patients waitlisted for KT

Transplanting a HCV- NAT positive deceased donor kidney followed by post-transplant direct acting anti-viral administration

Remaining on the waitlist for a kidney transplant from an HCV NAT- negative donor

ICER is US$ 56,018 if receiving a HCV NAT positive kidney shortens the wait-time by 1 year. Remaining on the waitlist for 2 or more years is dominated^b compared to receiving a HCV NAT positive kidney

US $ 50,000

PSA, SA

Robust

 Kiberd et al. [27]

Patients waitlisted for KT

Allocation polices based on donor and recipient HCV status

Comparison between each option

Option (b) over option (c)—ICER US$ 18,760/QALY.

Option (a) over option (b)—Dominated^b

Option (c) over option (a)—Dominant^a

Not mentioned

SA

Variable

discard all HCV⁺ donors

screen all donors and transplant infected organs into HCV⁺ recipients only

ignore HCV status and transplant without screening

 Schweitzer et al. [34]

Patients waitlisted for KT

Transplant kidneys from both standard donors and CDC-IRDs

Only transplant kidneys from standard donors. Discard kidneys from CDC-IRDs

Dominant^a

Not mentioned

OW, SA

Robust

CUA of kidney allocation policies (n = 09)

 Axelrod et al. [21]

Patients waitlisted for KT

KDPI ≤85 DKT

Patients continuing on HD

US $ 83/QALY

US $ 100,000

Not done

–

KDPI >85 DKT

US $ 32,870/QALY

PHS increased risk DKT

US $ 7944/QALY

HLA 0‐3 mismatch LKT

Dominant^a

HLA 4‐6 mismatch LKT

Dominant^a

ABOi LKT

US $ 34,755/QALY

ILKT

US $ 102,859/QALY

 Smith et al. [35]

Patients waitlisted for KT

A policy of transplanting the top 20% of the KDPI to candidates in the top 20% of expected survival

Conventional allocation policy

Dominant^a

Not mentioned

OW

Robust

 Mutinga et al. [31]

Patients waitlisted for KT

HLA-B locus not matched before kidney allocation

HLA-B locus matched before kidney allocation

US $ 7300 cost saving per lost QALY

Not mentioned

PSA, SA

Robust

 Schnitzler et al. [33]

Patients waitlisted for KT

Accepting a ECD kidney

Accepting a standard kidney

ICER value not mentioned.

SD US $ 56,058/QALY

ECD US $ 72,838/QALY

Not mentioned

OW

Robust

 Bavanandan et al. [23]

Patients waitlisted for KT

Kidney transplantation using live donors

Kidney transplantation using deceased donors

Dominant^a

Not mentioned

OW

Robust

 Snyder et al. [36]

Patients waitlisted for KT

A waitlist with both DBD and DCD kidneys

A waitlist only with DBD

Dominant^a

Not mentioned

OW, TW, PSA

Robust

 Cavallo et al. [24]

Patients waitlisted for KT

Assumption of 10 extra DCD transplants per year after implementing the programme Alba [40]

Baseline practice

US $ 7025/QALY

Not mentioned

OW

Variable

Assumption of 10% extra transplants from each donation type (DCD, DBD, live) per year after implementing the programme Alba [40]

Baseline practice

Dominant^a

OW

Variable

 Barnieh et al. [22]

Patients waitlisted for KT

A payment of US $8000 (2010) to all the living donors, which would expect the annual transplant rate to increase by 5%.

Current KT practice

Dominant^a

Not mentioned

OW, TW, PSA

Variable

 Matas et al. [29]

Patients waitlisted for KT

Patients receiving a paid living unrelated donor kidney

Patients continuing on HD

It would be cost-effective to add one vendor to the donor pool if the payment made to that vendor for donation was no more than US $351,065

Not mentioned

OW

Variable

CUA of technology used in KT (n = 04)

 Nguyen et al. [32]

KT recipients (DKT and LKT)

Using bead-based multiplex assays (threshold MFI level 500) with CDC

Only CDC

Dominant^a

Not mentioned

OW, PSA

Robust

 McLaughlin et al. [30]

Patients undergoing DKT

Flow screening only, where patients’ immunological risks were stratified using the results of FCXM and flow micro-bead PRA

Serological screening only, where patients’ immunological risks were stratified using the result of AHG enhanced CDCXM and PRA titer only

Dominant^a

Not mentioned

OW

Robust

 Groen et al. [25]

Patients undergoing KT

Hypothermic machine preservation as the organ preservation method in KT

Use of Static cold storage

Dominant^a

Not mentioned

Bootstrapping

Robust

 Liem et al. [28]

Live kidney donors undergoing pre-operative imaging

Different combinations of strategies; MRIA, SCTA, DSA with MRA, MRIA and DSA if MRIA inconclusive, MRIA with SCTA

Pre-operative imaging DSA

DSA dominated all the imaging strategies

Not mentioned

OW, TW

Variable